Evidence map›Paper›PMID 34954559›Full record

ArticleInternational immunopharmacology2022

Response kinetics of different classes of antibodies to SARS-CoV2 infection in the Japanese population: The IgA and IgG titers increased earlier than the IgM titers.

Makoto Kurano, Yoshifumi Morita, Yuki Nakano, Rin Yokoyama, Takuya Shimura, Chungen Qian, Fuzhen Xia, Fan He, Liang Zheng, Hiroko Ohmiya and 15 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International immunopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 7 institutions in 2 countries.

Makoto KuranoDepartment of Clinical Laboratory, the University of Tokyo Hospital, Tokyo, Japan; Department of Clinical Laboratory Medicine, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan. Electronic address: kurano-tky@umin.ac.jp.
Yoshifumi MoritaDepartment of Clinical Laboratory, the University of Tokyo Hospital, Tokyo, Japan.
Yuki NakanoDepartment of Clinical Laboratory, the University of Tokyo Hospital, Tokyo, Japan.
Rin YokoyamaDepartment of Clinical Laboratory, the University of Tokyo Hospital, Tokyo, Japan.
Takuya ShimuraDepartment of Clinical Laboratory, the University of Tokyo Hospital, Tokyo, Japan.
Chungen QianThe Key Laboratory for Biomedical Photonics of MOE at Wuhan National Laboratory for Optoelectronics - Hubei Bioinformatics & Molecular Imaging Key Laboratory, Systems Biology Theme, Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Hubei, P.R. China.
Fuzhen XiaReagent R&D Center, Shenzhen YHLO Biotech Co., Ltd, Guangdong, PR China.
Fan HeReagent R&D Center, Shenzhen YHLO Biotech Co., Ltd, Guangdong, PR China.
Liang ZhengReagent R&D Center, Shenzhen YHLO Biotech Co., Ltd, Guangdong, PR China.
Hiroko OhmiyaBusiness Planning Department, Sales & Marketing Division, Medical & Biological Laboratories Co., Ltd, Tokyo, Japan.
Yoshiro KishiBusiness Planning Department, Sales & Marketing Division, Medical & Biological Laboratories Co., Ltd, Tokyo, Japan.
Jun OkadaBusiness Planning Department, Sales & Marketing Division, Medical & Biological Laboratories Co., Ltd, Tokyo, Japan.
Naoyuki YoshikawaDepartment of Clinical Laboratory, the University of Tokyo Hospital, Tokyo, Japan.
Kazuki NakajimaDepartment of Blood Transfusion, the University of Tokyo Hospital, Tokyo, Japan.
Yutaka NaguraDepartment of Blood Transfusion, the University of Tokyo Hospital, Tokyo, Japan.
Hitoshi OkazakiDepartment of Blood Transfusion, the University of Tokyo Hospital, Tokyo, Japan.
Daisuke JubishiDepartment of Infection Control and Prevention, The University of Tokyo, Tokyo, Japan.
Kyoji MoriyaDepartment of Infection Control and Prevention, The University of Tokyo, Tokyo, Japan.
Yasuyuki SetoDepartment of Gastrointestinal Surgery, The University of Tokyo, Japan.
Fumihiko YasuiTokyo Metoropolitan Institute of Medical Research, Tokyo, Japan.
Michinori KoharaTokyo Metoropolitan Institute of Medical Research, Tokyo, Japan.
Masatoshi WakuiDepartment of Laboratory Medicine, Keio University School of Medicine.
Takeshi KawamuraLaboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan; Isotope Science Center, The University of Tokyo, Tokyo, Japan.
Tatsuhiko KodamaLaboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
Yutaka YatomiDepartment of Clinical Laboratory, the University of Tokyo Hospital, Tokyo, Japan; Department of Clinical Laboratory Medicine, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan. Electronic address: yatoyuta-tky@umin.ac.jp.
University of Tokyo Hospital · JPThe University of Tokyo · JPMedical & Biological Laboratories (Japan) · JPTokyo Metropolitan Institute of Medical Science · JPKeio University · JPTokyo University of Science · JPWuhan National Laboratory for Optoelectronics · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To better understand the immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in individuals with COVID-19, it is important to investigate the kinetics of the antibody responses and their associations with the clinical course in different populations, since there seem to be considerable differences between Western and Asian populations in the clinical features and spread of COVID-19. In this study, we serially measured the serum titers of IgM, IgG and IgA antibodies generated against the nucleocapsid protein (NCP), S1 subunit of the spike protein (S1), and receptor-binding domain in the S1 subunit (RBD) of SARS-CoV-2 in Japanese individuals with COVID-19. Among the IgM, IgG, and IgA antibodies, IgA antibodies against all of the aforementioned viral proteins were the first to appear after the infection, and IgG and/or IgA seroconversion often preceded IgM seroconversion. In regard to the timeline of the antibody responses to the different viral proteins (NCP, S1 and RBD), IgA against NCP appeared than IgA against S1 or RBD, while IgM and IgG against S1 appeared earlier than IgM/IgG against NCP or RBD. The IgG responses to all three viral proteins and responses of all three antibody classes to S1 and RBD were sustained for longer durations than the IgA/IgM responses to all three viral proteins and responses of all three antibody classes to NCP, respectively. The seroconversion of IgA against NCP occurred later and less frequently in patients with mild COVID-19. These results suggest possible differences in the antibody responses to SARS-CoV-2 antigens between the Japanese and Western populations.

Indexed as

SARS-CoV-2Antibody FormationAsian PeopleCOVID-19HumansImmunoglobulin AImmunoglobulin GImmunoglobulin MJapanSeroconversionViral ProteinsImmunoglobulin AImmunoglobulin GImmunoglobulin MViral ProteinsCOVID-19IgAIgGIgMJapanese populationKinetics of antibody responsesNucleocapsid proteinReceptor-binding domainSpike protein

Identifiers

PMID34954559
PMCPMC8687758
OpenAlexW4200041709

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.